semaglutide weight loss arboretum in Arizona Semaglutide –

(Kailera), a clinical-stage biopharmaceutical company focused on advancing a differentiated, late-stage portfolio of next-generation therapies for the treatment of obesity, today announced the presentation of additional data from Hengruis Phase 3 clinical trial 1 (GEMINI-1) of a once-weekly subcutaneous injection of HRS9531, a novel dual GLP-1/GIP receptor agonist, in individuals living with obesity or overweight in China (NCT06396429) at ObesityWeek 2025, the annual meeting of The Obesity Society (TOS)

These labels can be found starting in January

Semaglutide+ starts as low as $99.97/mo, and Tirzepatide+ as low as $144.49/mo, with the same price across all doses

PGC1, peroxisome proliferator-activated receptor-gamma coactivator 1

However, like all medications, it can have side effects